India, June 18 -- Legend Biotech Corporation (LEGN) has priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS, raising approximately $226 million in gross proceeds before underwriting discounts and expenses. Each ADS represents two ordinary shares of the company.
The underwriters have been granted a 30-day option to purchase up to an additional 1.155 million ADSs at the offering price, excluding fees and commissions. All ADSs in the offering are being sold by Legend Biotech.
The company said the offering is expected to close on June 23, 2026, subject to customary closing conditions. Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are acting as joint book-running manage...